Načítá se...
Optimizing Early “Go/No Go” Decisions in CNS Drug Development
Go/No Go decisions concerning development of any single compound determine investment in increasingly costly studies from Phase 1–3. Such decisions are problematic for CNS drug development where the variety of molecular targets in the brain have stimulated decades of studies without major therapeuti...
Uloženo v:
| Vydáno v: | Expert Rev Clin Pharmacol |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4648539/ https://ncbi.nlm.nih.gov/pubmed/25537256 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/17512433.2015.991715 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|